Yehuda Handelsman, MD: The World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease Preview

December 2, 2020
HCP Live

Strategic Alliance Partnership | <b>The Metabolic Institute of America</b>

The TMIOA Medical Director highlights the best sessions, new topics, and growing discussion around the 18th annual congress.


The 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference kicks off this Thursday morning, ushering in a new era of education tools and interactivity from the longstanding annual meeting.

As similar meetings had to resolve in this past year due to the coronavirus 2019 (COVID-19) pandemic, the four-day WCIRDC meeting moved to a completely virtual format for this year, bolstering its offering of archived, online-accessible materials for a litany of clinicians and specialists engaged in the fields of insulin and cardiovascular care.

Indeed, such a field is rapidly growing, and is evolving to include specialists associated from better understood patient comorbidities and risks. This year’s WCIRDC agenda reflects the sheer variety and reach of the insulin and cardiovascular care fields, now providing an additional day’s worth of content and insights to ensure everything is covered.

Leading up to this weekend’s meeting, HCPLive® spoke with WCIDRC Program Chair Yehuda Handelsman, MD, Medical Director and Principal Investigator at the Metabolic Institute of America.

Handelsman shared insights into the makeup of this year’s pivotal meeting agenda, the thought process behind key additions and new topics, the sessions which he is particularly looking forward to most, and what he could see the annual meeting applying from this year into its 2021 agenda.

Be sure to click through the videos above to watch Handelsman’s preview of the meeting, check out HCPLive later this week for exclusive video interviews with WCIRDC presenters, and register for the meeting here.


x